Citations

Clear

3942 citation(s) found for "To, Van".

Vascular burden and Alzheimer disease pathologic progression
Lo, Raymond Y. , Jagust, William J. , Weiner, Michael W. , Aisen, Paul , Petersen, Ronald , Trojanowki, John Q., Liu, Enchi , Montine, Tom, Petersen, Ronald, Gamst, Anthony, Thomas, Ronald G. , Walter, Sarah , Gessert, Devon, Sather, Tamie, Kornak, John , Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene, DeCarli, Charles , Bandy, Dan, Foster, Norm, Reiman, Eric M. , Mathis, Chet, Cairns, Nigel J., Taylor‐Reinwald, Lisa, Shaw, Les, Korecka, Magdalena , Crawford, Karen , Neu, Scott, Foroud, Tatiana M., Potkin, Steven, Kachaturian, Zaven, Frank, Richard , Molchan, Susan, Quinn, Joseph, Lind, Betty, Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan M., Brewer, James, Vanderswag, Helen, Heidebrink, Judith L. , Johnson, Kris , Doody, Rachelle S., Villanueva‐Meyer, Javier , Chowdhury, Munir , Bell, Karen L. , Carroll, Maria , Leon, Sue, Mintun, Mark A., Schneider, Stacy, Marson, Daniel , Griffith, Randall, Clark, David, Grossman, Hillel, Mitsis, Effie, Romirowsky, Aliza, deToledo‐Morrell, Leyla, Duara, Ranjan , Varón, Daniel , Roberts, Peggy, Albert, Marilyn, Onyike, Chiadi, Kielb, Stephanie , Glodzik, Lidia , Santi, Susan De , Doraiswamy, P. Murali , Petrella, Jeffrey R. , Coleman, R. Edward, Arnold, Steven E. , Karlawish, Jason H., Smith, Charles D., Jicha, Gregory A. , Hardy, Peter , Oakley, MaryAnn, Simpson, Donna M., Goldstein, Bonnie S., Martin, Kim, Makino, Kelly M., Ismail, M. Saleem , Brand, Connie, Mulnard, Ruth A., Thai, Gaby , Mc-Adams-Ortiz, Catherine, Mathews, Dana, Quiceno, Mary , King, Richard, Weiner, Myron, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Swerdlow, Russell H. , Apostolova, Liana , Lu, Po H. , Bartzokis, George, Graff‐Radford, Neill R. , Parfitt, Francine, Farlow, Martin R. , Hake, Ann Marie , Matthews, Brandy R., Herring, Scott, Dyck, Christopher H. van , Carson, Richard E. , MacAvoy, Martha G., Chertkow, Howard , Bergman, Howard , Hosein, Chris, Black, Sandra, Stefanovic, Dr Bojana, Caldwell, Curtis, Hsiung, Ging‐Yuek Robin , Mudge, Benita, Assaly, Michele, Kertesz, Andrew, Rogers, John, Trost, Dick, Bernick, Charles , Munic, Donna, Mesulam, Marek-Marsel, Lipowski, Kristina, Wu, Chuang‐Kuo, Johnson, Nancy , Sadowsky, Carl, Villena, Teresa, Johnson, Kathleen, Reynolds, Brigid, Johnson, Keith A., Marshall, Gad A. , Frey, Meghan , Yesavage, Jerome A. , Taylor, Joy L. , Lane, Barton , Rosen, Allyson , Tinklenberg, Jared, Sabbagh, Marwan N. , Belden, Christine M. , Jacobson, Sandra A. , Kowall, Neil W. , Budson, Andrew E. , Johnson, Patricia Lynn, Wolday, Saba, Bwayo, Salome K., Lerner, Alan J. , Hudson, Leon, Ogrocki, Paula, Fletcher, Evan, Olichney, John , Kittur, Smita, Borrie, Michael, Lee, T‐Y, Bartha, Dr Rob, Asthana, Sanjay , Carlsson, Cynthia M., Preda, Adrian , Tariot, Pierre N. , Fleisher, Adam , Reeder, Stephanie, Bates, Vernice, Capote, Horacio, Rainka, Michelle, Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Blank, Karen, Anderson, Karen, Santulli, Robert B. , Schwartz, Eben S., Williamson, Jeff D. , Garg, Pradeep , Watkins, Franklin, Ott, Brian R. , Querfurth, Henry, Tremont, Geoffrey , Salloway, Stephen , Malloy, Paul, Correia, Stephen , Rosen, Howard J. , Mintzer, Jacobo , Longmire, Crystal Flynn, Spicer, Kenneth, Rachinsky, Irina, Rogers, John , Drost, Dick, Lee, Ting‐Yim , Jack, Clifford R. , Toga, Arthur W. , Beckett, Laurel , Green, Robert C. , Saykin, Andrew J. , Morris, John C. , Donohue, Michael , Harvey, Danielle , Dale, Anders M. , Bernstein, Matt A. , Fox, Nick C. , Thompson, Paul M. , Koeppe, Robert A. , Chen, Kewei , Mathis, Chet, Lee, Virginia M.‐Y. , Shen, Li , Snyder, Peter J. , Kaye, Jeffrey , Lord, Joanne L. , Stern, Yaakov , Honig, Lawrence S. , Ances, Beau M. , Shah, Raj C. , Duara, Ranjan , Rusinek, Henry , Leon, Mony J. de , Karlawish, Jason , Wolk, David A. , López, Oscar L. , Porsteinsson, Anton P. , Womack, Kyle , Diaz‐Arrastia, Ramon , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather K. , Stefanovic, Bojana , Feldman, Howard , Kerwin, Diana , Martínez, Walter Fabián , Turner, Raymond Scott , Sperling, Reisa Anne , Killiany, Ronald , Norbash, Alexander , Obisesan, Thomas O. , Carmichael, Owen , Johnson, Sterling C. , Nguyen, Dana R. , Reeder, Stephanie, Scharre, Douglas W. , Pearlson, Godfrey D. , Sink, Kaycee M. , Miller, Bruce L. , Finger, Elizabeth C. , Preda, Adrian , Hsiung, Gink-Yuek , Jicha, Gregory A

Mayo Clinic

Neurology | September 13, 2012 | Volume: 79 | Issue: 13 | Pages: 1349-1355

10.1212/wnl.0b013e31826c1b9d | PMID 22972646 Get It

Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function
Fuchsberger, Christian , Teumer, Alexander , Böger, Carsten A., Endlich, Karlhans , Olden, Matthias , Chen, Ming‐Huei , Li, Man , Gao, Xiaoyi , Gorski, Mathias , Hundertmark, Claudia, Foster, Meredith C., O’Seaghdha, Conall M. , Glazer, Nicole L. , Isaacs, Aaron , Liu, Ching‐Ti , Smith, Albert V. , O’Connell, Jeffrey R. , Struchalin, Maksim , Johnson, Andrew D. , Gierman, Hinco J. , Feitosa, Mary F. , Hwang, Shih-Jen, Atkinson, Elizabeth J. , Lohman, Kurt, Cornelis, Marilyn C., Johansson, Åsa , Tönjes, Anke , Dehghan, Abbas , Lambert, Jean‐Charles , Holliday, Elizabeth G., Sorice, Rossella , Kutalik, Zoltán , Lehtimäki, Terho , Esko, Tõnu , Deshmukh, Harshal , Ulivi, Sheila , Chu, Audrey Y., Murgia, Federico , Trompet, Stella , Imboden, Medea , Coassin, Stefan , Pistis, Giorgio , WTCCC2, Harris, Tamara B., Aspelund, Thor , Eiríksdóttir, Guðný , Mitchell, Braxton D. , Boerwinkle, Eric , Schmidt, Helena , Cavalieri, Margherita, Rao, Madhumathi , Hu, Frank B., Demirkan, Ayşe , Oostra, Ben A., Ding, Jingzhong , Andrews, Jeanette S., Giulianini, Franco, Köenig, Wolfgang , Illig, Thomas, Meisinger, Christa , Gieger, Christian , Zgaga, Lina , Zemunik, Tatijana , Boban, Mladen , Wheeler, Heather E. , Igl, Wilmar , Zaboli, Ghazal, Wright, Alan F., Campbell, Harry, Ellinghaus, David , Nöthlings, Ute , Jacobs, Gunnar, Biffar, Reiner , Ernst, Florian , Kroemer, Heyo K., Stracke, Sylvia , Völker, Uwe , Völzke, Henry , Kovács, Péter , Stümvoll, Michael , Mägi, Reedik , Hofman, Albert , Uitterlinden, André G. , Rivadeneira, Fernando , Aulchenko, Yurii S. , Polašek, Ozren , Hastie, Nick, Vitart, Véronique , Helmer, Catherine , Wang, Jie Jin , Stengel, Bénédicte , Ruggiero, Daniela , Kähönen, Mika , Viikari, Jorma , Nikopensius, Tiit , Province, Michael A. , Ketkar, Shamika , Colhoun, Helen M. , Doney, Alex S. F. , Robino, Antonietta , Krämer, Bernhard K. , Portas, Laura , Ford, Ian, Adam, Martin , Thun, Gian Andri , Paulweber, Bernhard , Haun, Margot, Sala, Cinzia , Mitchell, Paul, Ciullo, Marina , Kim, Stuart K. , Vollenweider, Péter , Raitakari, Olli T., Palmer, Colin, Gasparini, Paolo , Pirastu, Mario, Jukema, J. Wouter , Kronenberg, Florian , Toniolo, Daniela , Guðnason, Vilmundur , Shuldiner, Alan R. , Schmidt, Reinhold, Ferrucci, Luigi , Duijn, Cornelia M. van , Borecki, Ingrid B. , Kardia, Sharon L. R., Rudan, Igor , Pramstaller, Peter P. , Rettig, Rainer, Prokopenko, Inga , Witteman, Jacqueline C.M., Hayward, Caroline , Ridker, Paul M., Parsa, Afshin, Bochud, Murielle , Heid, Iris M. , Kao, W.H. Linda , Fox, Caroline S., Köttgen, Anna , Palmer, Colin N.A. , Chasman, Daniel I. , Pattaro, Cristian , Tin, Adrienne , Taliun, Daniel , Yang, Qiong , Tanaka, Toshiko , Guo, Li , Holliday, Elizabeth G., WTCCC2, Launer, Lenore J. , Andrade, Mariza de , Turner, Stephen T. , Freedman, Barry I. , Minelli, Cosetta , Wild, Sarah H. , Ellinghaus, David , Homuth, Georg , Nauck, Matthias A. , Bergmann, Sven M. , Buckley, Brendan Martin , Metspalu, Andres , Palmer, Colin, Probst-Hensch, Nicole M , Coresh, Josef , Siscovick, David S. , Curhan, Gary C. , Gyllensten, Ulf B , Wilson, James Fox , Franke, André , Palmer, Colin N A , Colhoun, Helen M , Völker, Uwe , Teumer, Alexander , van Duijn, Cornelia M , Smith, Albert V , Mitchell, Braxton D , Shuldiner, Alan R , Ferrucci, Luigi , Koenig, Wolfgang , Kovacs, Peter , Stracke, Sylvia , Liu, Ching-Ti , Wheeler, Heather E , Province, Mike

Mayo Clinic

Human Molecular Genetics | September 8, 2012 | Volume: 21 | Issue: 24 | Pages: 5329-5343

10.1093/hmg/dds369 | PMID 22962313 Get It

Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit
Naylor, Mary D. , Karlawish, Jason , Arnold, Steven E. , Khachaturian, Ara S. , Khachaturian, Zaven S., Baumgart, Matthew, Banerjee, Sube , Beck, Cornelia, Blennow, Kaj , Brookmeyer, Ron , Brunden, Kurt R. , Buckwalter, Kathleen C., Comer, Meryl, Covinsky, Kenneth E. , Feinberg, Lynn Friss, Frisoni, Giovanni B. , Guimarães, Renato Maia, Gwyther, Lisa P., Hutton, Michael , Kawas, Claudia H. , Kent, David M. , Kuller, Lewis H. , Langa, Kenneth M. , Mahley, Robert W. , Maslow, Katie, Masters, Colin L. , Meier, Diane E. , Neumann, Peter J. , Paul, Steven M., Petersen, Ronald C. , Sager, Mark A., Sano, Mary , Schenk, Dale, Soares, Holly , Stahl, Sidney M., Stern, Yaakov , Weir, David R. , Trojanowski, John Q. , Frisoni, Giovanni B. , Lee, Virginia M.‐Y. , Green, Colin Richard , Hefti, Franz F. , Sperling, Reisa Anne , Deerlin, Vivianna M. Van , Wolk, David A. , Stern, Yaakov , Masters, Colin L , Kent, David M

Mayo Clinic

Alzheimer's & Dementia | September 7, 2012 | Volume: 8 | Issue: 5 | Pages: 445-452

10.1016/j.jalz.2012.08.001 | PMID 22959699 Get It

AbstractTo address the pending public health crisis due to Alzheimer's disease (AD) and related neurodegenerative disorders, the Marian S. Ware Alzheimer Program at the University of Pennsylvania held a meeting entitled “State of the Science Conference on the Advancement of Alzheimer's Diagnosis, Treatment and Care,” on June 21‐22, 2012. The meeting comprised four workgroups focusing on Biomarkers; Clinical Care and Health Services Research; Drug Development; and Health Economics, Policy, and Ethics. The workgroups shared, discussed, and compiled an integrated set of priorities, recommendations, and action plans, which are presented in this article.
Human Lupus Serum Induces Neutrophil-Mediated Organ Damage in Mice That Is Enabled by Mac-1 Deficiency
Rosetti, Florencia , Tsuboi, Naotake , Nishi, Hiroshi , Ernandez, Thomas , Sethi, Sanjeev , Croce, Kevin , Stavrakis, George, Alcocer‐Varela, Jorge, Gómez‐Martín, Diana , Rooijen, Nico van , Lichtman, Andrew H., Mayadas, Tanya N. , Chen, Kan , Kyttaris, Vasileios C. , Tsokos, George C.

Mayo Clinic

The Journal of Immunology | August 30, 2012 | Volume: 189 | Issue: 7 | Pages: 3714-3723

10.4049/jimmunol.1201594 | PMID 22933624 Get It

Abstract Systemic lupus erythematosus (SLE) is a chronic, multiorgan inflammatory autoimmune disorder associated with high levels of circulating autoantibodies and immune complexes. We report that passive transfer of human SLE sera into mice expressing the uniquely human FcγRIIA and FcγRIIIB on neutrophils induces lupus nephritis and in some cases arthritis only when the mice additionally lack the CD18 integrin, Mac-1. The prevailing view is that Mac-1 on macrophages is responsible for immune complex clearance. However, disease permitted by the absence of Mac-1 is not related to enhanced renal immune complex deposition or in situ C1q/C3 complement activation and proceeds even in the absence of macrophages. Instead, disease is associated with increased FcγRIIA-induced neutrophil accumulation that is enabled by Mac-1 deficiency. Intravital microscopy in the cremasteric vasculature reveals that Mac-1 mitigates FcγRIIA-dependent neutrophil recruitment in response to deposited immune complexes. Our results provide direct evidence that human SLE immune complexes are pathogenic, demonstrate that neutrophils are primary mediators of end organ damage in a novel humanized lupus mouse model, and identify Mac-1 regulation of FcγRIIA-mediated neutrophil recruitment as a key step in development of target organ damage.
Abstract 3272: Characterization of mouse oviductal glycoprotein (Ovgp1) promoter driven SV40 T large antigen: fallopian tube cancer and leiomyosarcoma mouse model
Ota, Takayo , Marler, Ronald J., Clayton, Amy C., Zhang, Qing , Wei, Zhou, Shridhar, Viji , Deursen, Jan van, Araki, Yoshihiko , Miyoshi, Ichiro , Chien, Jeremy , Wei, Zhou, Chien, Jeremey

Mayo Clinic

Cancer Research | August 13, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: 3272-3272

10.1158/1538-7445.am2012-3272 Get It

Abstract Recent molecular and pathologic evidence indicate that high-grade serous carcinomas of the ovary, which are the most common type of epithelial carcinomas, may arise from the distal part of fallopian tubes or tubal carcinoma implants. Oviductal glycoprotein 1 (Ovgp1), a glycosylated protein found in the epithelial cells in the oviduct, is the only specific tubal marker so far. Ovgp1 promoter-driven SV40 large T-antigen transgenic mice develop tumors in the female reproductive organs. To characterize these tumors, we performed immunohistochemical analysis in paraffin-embedded sections. Mice were sacrificed at 8 or 13 weeks old. Macroscopically we observed large tumors in the uterus and cervix and markedly enlarged region in the oviduct. Due to the large tumor in the uterus and cervix, we could not keep the mice longer than 13 weeks. Histologically, there were no major differences in these affected regions between 8 weeks old and 13 weeks old mice. We observed, (i) relatively small ovaries and ovarian follicular hyperplasia, (ii) intact ovarian surface epithelium showing no atypical histology, (iii) atypical epithelial hyperplasia within the oviduct (with endometrioid architectural and cytologic features), (iv) leiomyosarcomatous proliferation in the myometrium, and (v) squamous carcinoma in situ in the cervix or early invasive cervical cancer with extensive papillary architecture. We did not detect metastasis from the tumor to other organs. The atypical abnormalities of the oviduct were more significant in the proximal site to the uterus than the distal site. The proximal oviduct demonstrated weak and spotty p53 expression, beneath the epithelium, similar to p53 signature in the human oviduct. We hypothesized that stem cell components may contribute to the tumor development and that putative cancer stem cells could be identified by stem cell markers. In the oviduct epithelium, Bmi1 expression was not detectable. Cytoplasmic expression of Sox2 was observed in all epithelial cells of the oviduct. There was little correlation between Sox2/Bmi1 staining and p53 staining in the oviduct. Interestingly, Sox2 and Bmi1 staining in the wild-type control mice showed immunoreactive cells interspersed between glandular structures, a pattern similar to previously described label-retaining cells in the endometrium. The expression pattern in Ovgp1-SV40 mice, Bmi1 and Sox2 expression were more obvious in the endometrial stromal area but not in the leiomyosarcoma region, which implies that stem cell components in the endometrial region may support the leiomyosarcoma progression in this mouse model. In conclusion, Ovgp1-SV40 transgenic mouse is a useful model for studies involving fallopian and lower genital tract carcinogenesis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3272. doi:1538-7445.AM2012-3272
Abstract LB-513: Abelson Interactor 1 is a novel substrate of protein kinase D2: potential implications in tumor cell migration
Nimmagadda, Subbaiah Chary, Eiseler, Tim , Störz, Peter , Seufferlein, Thomas , Lint, Johan Van

Mayo Clinic

Cancer Research | August 13, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: LB-513-LB-513

10.1158/1538-7445.am2012-lb-513 Get It

Abstract Introduction and Objective: The serine/threonine kinases of the protein kinase D family (PKCmu/PKD1, PKD2, PKCnu/PKD3), a subfamily of the CAMK superfamily, have been implicated in regulation of multiple biological processes including proliferation, survival, apoptosis, angiogenesis and motility. The precise mechanisms by which the three PKDs modulate these processes are incompletely understood and require a better knowledge of their signaling context. Methodology and Results: Using the ProtoArray Human Protein Microarray v4.0 (Invitrogen), we identified Abelson interactor 1 (ABI1) as a novel PKD2 substrate. ABI1 was first identified as the downstream target of Abl tyrosine kinase and is an adaptor protein involved in actin reorganization and lamellipodia formation along with WAVE2. In the present study we illustrate that PKD2 interacts and phosphorylates ABI1 in vitro and in vivo at two potential serine residues. The sites were validated using an antibody that specifically identifies the consensus PKD substrate sequence. Furthermore, PKD2-induced phosphorylation of ABI1 destabilized the interaction between ABI1 and WAVE2 and resulted in relocation of both the proteins from plasma membrane to perinuclear region. Consequences of this destabilization and its potential impact on WAVE2 driven actin polymerization and the associated processes are in the process of investigation. Preliminary results also suggest reduced migration velocity and directedness of a tumor cell. Conclusion: In conclusion, our data demonstrate that ABI1 is a novel substrate of PKD2 that might negatively regulate tumor cell migration via terminating a constitutive interaction between ABI1 and WAVE2. *Impact of ABI1-WAVE2 subcomplex destabilization on WAVE2 induced actin polymerization and lamellipodia extension will be presented at the meeting. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-513. doi:1538-7445.AM2012-LB-513
Abstract LB-423: Whole genome comparisons of pre- and post- aromatase inhibitor treatment in estrogen receptor positive breast cancer
Li, Ding, Shen, Dong , Wallis, John W., Tine, Brian Andrew Van, Crowder, Robert J., Snider, Jacqueline, Koboldt, Daniel C. , Schierding, William , McMichael, Joshua F. , Kandoth, Cyriac , Wendl, Michael C. , DeSchryver, Katherine, Allred, D. Craig, Unzeitig, Gary, Margenthaler, Julie, Babiera, Gildy V., Marcom, P. Kelly, Guenther, J. Michael, Leitch, Marilyn , Tao, Yu , Fulton, Lucinda , Fulton, Robert S. , Oberkfell, Ben, Du, Feiyu, Demeter, Ryan, Vickery, Tammi L. , McDonald, Sandra , Dooling, David J., Ota, David M., Chang, Li‐Wei , Bose, Ron , Wilson, Richard K. , Ellis, Matthew J. , Luo, Jingqin , Suman, Vera J. , Hoog, Jeremy , Ballman, Karla V. , Chen, Ken , Miller, Christopher A. , Lu, Charles , Harris, Christopher , McLellan, Michael D. , Esserman, Laura J. , Hunt, Kelly K. , Olson, John A. , Harrison, Michelle , Griffith, Malachi , Watson, Mark A. , Ley, Timothy James , Mardis, Elaine R.

Mayo Clinic

Cancer Research | August 13, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: LB-423-LB-423

10.1158/1538-7445.am2012-lb-423 Get It

Abstract Background: Estrogen receptors are over-expressed in around 70% of breast cancer cases. The genetic changes that occur during aromatase inhibitor (AI) treatment are not well understood and may differ depending upon the patient's response phenotype. Methods: We performed whole genome sequencing (WGS) of matched blood, pre-treatment, and post-treatment biopsy samples from 22 estrogen receptor positive breast cancer patients treated with neoadjuvant aromatase inhibitors. For 5 cases, we performed the whole genome sequencing (WGS) on patients’ matched normal, two pre AI-treatment, and two post AI-treatment DNA isolates from biopsy samples. We validated all putative coding and non-coding somatic mutations using deep sequencing. By comparing the validated somatic mutations from pre- and post- AI treatment biopsy samples, we were able to determine the alterations in the tumor genomes. In every case we defined the clonal architecture of each pair of pre-treatment and post-treatment biopsy samples by comparing the variant allele frequencies from thousands of validated somatic mutations. Results: Comparisons of the two pre AI-treatment biopsy samples from the same patient indicates that the variant allele frequencies of mutations showed high concordances in all 5 cases, 0.74 to 0.95 range of correlation coefficient. Only a small percentage of somatic mutations were detected in one pre-treatment sample and not the other (4.65% overall). In comparing the somatic variations between pre-treatment and matched post-treatment biopsy samples in 22 cases, we found that patients with good clinical response to AI treatment retained known driver mutations only in their pre-treatment tumors. Conversely, those patients with poor clinical response presented new driver mutations in their post-treatment samples. Furthermore, the variant allele frequency for most mutated genes decreased in post AI treatment samples for patients with good AI treatment response; on the contrary, the variant allele frequency increased for patients with poor clinical response. Conclusions: From WGS of matched normal, pre-treatment, and post-treatment biopsy samples, we identified new driver genes mutated in patients with poor clinical response, while patients with good clinical response had lost mutated driver genes in their post-treatment biopsy samples. The genetic landscape revealed by WGS of pre-treatment and post-treatment biopsy samples reveals mutational repertoires are remodeled by AI therapy. This finding suggests deep sequencing of AI treated samples will be necessary to reveal the complete complement of mutations present in a patient's tumor. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-423. doi:1538-7445.AM2012-LB-423
BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk
Spurdle, Amanda B. , Whiley, Phillip J , Thompson, Bryony A. , Feng, Bing , Healey, Sue, Brown, Melissa A. , Pettigrew, Christopher A. , kConFab, Ausems, Margreet G.E.M. , Kattentidt-Mouravieva, A.A., Ouweland, Ans M.W. van den, Lindblom, Annika , Pigg, Maritta Hellström, Schmutzler, Rita K., Engel, Christoph , Meindl, Alfons , Caputo, Sandrine M. , Sinilnikova, Olga M., Lidereau, Rosette, collaborators, French COVAR group, Guidugli, Lucia, Hansen, Thomas van Overeem , Thomassen, Mads , Eccles, Diana M, Tucker, Kathy , Rensburg, Elizabeth J. van , Wappenschmidt, Barbara, Borg, Åke , Goldgar, David E. , Nathanson, Katherine L. , Devilee, Peter , Gómez, E. , Gerdes, Anne‐Marie , Luijt, Rob B. van der , Eccles, Diana , Mazoyer, Sylvie , Castéra, Laurent , Krieger, Sophie , kConFab, Asperen, Christi J. van , Meindl, Alfons , collaborators, French COVAR group, Couch, Fergus J. , Eccles, Diana M, Benı́tez, Javier , Domchek, Susan M. , Toland, Amanda Ewart , Vreeswijk, Maaike P.G. , Spurdle, Amanda B , van Rensburg, Elizabeth J , Eccles, Diana , van der Luijt, Rob B , Nathanson, Katherine L , Engel, Christoph , Gómez-García, Encarna B , Hansen, Thomas van Overeem , Devilee, Peter , Lindblom, Annika

Mayo Clinic

Journal of Medical Genetics | August 13, 2012 | Volume: 49 | Issue: 8 | Pages: 525-532

10.1136/jmedgenet-2012-101037 | PMID 22889855 Get It

Background Clinical classification of rare sequence changes identified in the breast cancer susceptibility genes BRCA1 and BRCA2 is essential for appropriate genetic counselling of individuals carrying these variants. We previously showed that variant BRCA1 c.5096G>A p.Arg1699Gln in the BRCA1 transcriptional transactivation domain demonstrated equivocal results from a series of functional assays, and proposed that this variant may confer low to moderate risk of cancer. Methods Measures of genetic risk (report of family history, segregation) were assessed for 68 BRCA1 c.5096G>A p.Arg1699Gln (R1699Q) families recruited through family cancer clinics, comparing results with 34 families carrying the previously classified pathogenic BRCA1 c.5095C>T p.Arg1699Trp (R1699W) mutation at the same residue, and to 243 breast cancer families with no BRCA1 pathogenic mutation (BRCA-X). Results Comparison of BRCA1 carrier prediction scores of probands using the BOADICEA risk prediction tool revealed that BRCA1 c.5096G>A p.Arg1699Gln variant carriers had family histories that were less ‘ BRCA1 -like’ than BRCA1 c.5095C>T p.Arg1699Trp mutation carriers (p<0.00001), but more ‘ BRCA1 -like’ than BRCA-X families (p=0.0004). Further, modified segregation analysis of the subset of 30 families with additional genotyping showed that BRCA1 c.5096G >A p.Arg1699Gln had reduced penetrance compared with the average truncating BRCA1 mutation penetrance (p=0.0002), with estimated cumulative risks to age 70 of breast or ovarian cancer of 24%. Conclusions Our results provide substantial evidence that the BRCA1 c.5096G>A p.Arg1699Gln (R1699Q) variant, demonstrating ambiguous functional deficiency across multiple assays, is associated with intermediate risk of breast and ovarian cancer, highlighting challenges for risk modelling and clinical management of patients of this and other potential moderate-risk variants.
Abstract 5104: Identification of key tumorigenic pathways in pancreatic adenocarcinoma patients using massively parallel DNA and RNA sequencing
Craig, David W. , Carpten, John D. , Demeure, Michael J. , Kiefer, Jeffrey , Posner, Richard G. , Izatt, Tyler, Sinari, Shripad, Christoforides, Alexis, Aldrich, Jessica, Kurdoglu, Ahmet, Benson, Hollie, Baker, Angela , Han, Haiyong , Lake, Douglas F. , Ramanathan, Ramesh K., Stewart, A. Keith, Hoff, Daniel D. Von , Liang, Winnie S. , Borad, Mitesh J. , Weiss, Glen J. , Hostetter, Galen H. , Phillips, L Taylor , Stites, Edward C. , Fonseca, Rafaël

Mayo Clinic

Cancer Research | August 9, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: 5104-5104

10.1158/1538-7445.am2012-5104 Get It

Abstract Purpose: Pancreatic adenocarcinoma is among the most lethal forms of all malignancies. While significant research has implicated multiple genes in disease pathogenesis, identification of therapeutic leads has been difficult. The majority of currently available therapies provide only marginal benefit. To address this issue, our goal was to assess global somatic events across multiple pancreatic tumors by using next-generation sequencing technologies (NGS). Experimental Design: We performed whole genome sequencing (WGS) on paired tumor and normal samples from 3 pancreatic adenocarcinoma patients. Additionally, we performed whole transcriptome sequencing (WTS) on 2 of these patients’ tumors for which tumor RNA was available. Results: We generated on average 132 billion mappable bases across all patients using WGS, and identified 140 somatic coding events including point mutations, insertion/deletions, and chromosomal copy number variants. Data from WGS and WTS were integrated and analyzed to identify the most heavily affected pancreatic cancer pathways across all patients. The KRAS signaling pathway was identified as the most significant map. Unbiased global pathway analysis was also performed to identify processes that may be impacted. Consistent with the previous analysis, the most significant pathway from this analysis is also KRAS signaling. This integrated analysis specifically identifies heavily affected pathways in pancreatic cancer and pinpoints genes and processes that may be considered as targets for more effective therapies. Conclusions: While sequencing of additional patients is necessary to strengthen selection of key pathways, we demonstrate the utility of using NGS to understand the processes driving pancreatic adenocarcinoma so that standardized treatments for patients may be improved. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5104. doi:1538-7445.AM2012-5104
Abstract 5518: Clinicopathologic associations with colorectal cancer molecular pathways in a cohort study of older women
Sammader, N Jewel, Tillmans, Lori S. , Wang, Alice H., Weisenberger, Daniel J. , Lynch, Charles F. , Anderson, Kristin E. , French, Amy J. , Smyrk, Thomas C. , Thibodeau, Stephen N. , Vierkant, Robert A. , Laird, Peter W. , Haile, Robert W. , Harnack, Lisa , Potter, John D. , Slager, Susan L. , Cerhan, James R. , Limburg, Paul J.

Mayo Clinic

Cancer Research | August 9, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: 5518-5518

10.1158/1538-7445.am2012-5518 Get It

Abstract Background: Colorectal cancer (CRC) is a molecularly heterogeneous disease. Three molecular pathways (traditional, serrated and alternate) have been recently proposed based on integrated combinations of microsatellite instability (MSI), CpG island methylation phenotype (CIMP), BRAF mutation, and KRAS mutation status (Gastroenterol 2010;138:2088-2100). To our knowledge, clinicopathologic associations with these CRC pathways have not been previously described. Methods: Data and tissue resources were obtained from the population-based Iowa Women's Health Study, which recruited 41,836 randomly selected women, ages 55-69 years, at study entry (1986). Incident CRC cases were ascertained by annual linkage with the Iowa Cancer Registry. Archived, paraffin-embedded tissue specimens were collected from 732 CRC cases diagnosed through 12/31/2002. Established laboratory methods were used to characterize CRC cases by MSI (MSS/MSI-L or MSI-H), CIMP (neg, low, or high), BRAF mutation (wt or mut), and KRAS mutation (wt or mut) status. Molecular pathways were defined as: traditional (MSS/MSI-L, CIMP-neg, BRAF wt, and KRAS wt); serrated (any MSI, CIMP-high, BRAF mut, and KRAS wt), alternate (MSS/MSI-L, CIMP-low, BRAF wt, and KRAS mut), or other pathway. Chi-square tests and analyses of variance were used to compare clinicopathologic features at CRC presentation (age, anatomic subsite, tumor grade, and SEER stage) across the molecular pathways. Results: Comlete and informative MSI, CIMP, BRAF and KRAS data were obtained for 491/732 (67%) CRC cases. Clinicopathologic associations are shown in the Table. Conclusions: These data suggest that distributions of age at diagnosis, subsite, and tumor grade, but not SEER stage, differ across the traditional, serrated, and alternate carcinogenic pathways, which may have implications for molecularly-targeted CRC prevention and/or therapy strategies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5518. doi:1538-7445.AM2012-5518